NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) has been assigned a consensus recommendation of “Hold” from the eight analysts that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $6.60.
NBY has been the subject of a number of research analyst reports. ValuEngine cut NovaBay Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, November 10th. Zacks Investment Research cut NovaBay Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, September 28th. lowered their price target on NovaBay Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, November 15th. Roth Capital set a $5.00 price target on NovaBay Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, October 23rd. Finally, HC Wainwright set a $6.00 price target on NovaBay Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, November 15th.
Shares of NovaBay Pharmaceuticals (NBY) opened at $3.70 on Tuesday. The stock has a market capitalization of $56.92, a price-to-earnings ratio of -5.78 and a beta of -0.70. NovaBay Pharmaceuticals has a twelve month low of $2.25 and a twelve month high of $5.00.
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) last released its quarterly earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.09). The business had revenue of $4.09 million for the quarter, compared to analysts’ expectations of $4.69 million. NovaBay Pharmaceuticals had a negative return on equity of 184.30% and a negative net margin of 42.16%.
COPYRIGHT VIOLATION WARNING: This news story was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://transcriptdaily.com/2018/01/16/novabay-pharmaceuticals-inc-nby-given-consensus-rating-of-hold-by-analysts.html.
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.